GlaxoSmithKline plc (LSE:GSK) confirmed that consideration is being given to a potential transaction that includes a merger of GlaxoSmithKline Consumer Healthcare Limited (BSE:500676). Majority of Horlicks and other GlaxoSmithKline nutrition products sales are generated in India by GlaxoSmithKline Consumer Healthcare Limited.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,759 GBX | +1.66% | -0.95% | +21.20% |
30/05 | Goldman Sachs Starts GSK With Neutral Rating, $47 Price Target | MT |
30/05 | Goldman Sachs Initiates GlaxoSmithKline with Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.20% | 89.9B | |
+39.82% | 734B | |
+32.87% | 591B | |
-7.31% | 350B | |
+14.23% | 315B | |
+0.86% | 276B | |
+14.25% | 238B | |
-6.30% | 204B | |
+8.95% | 206B | |
+4.51% | 161B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GSK Says Considering Potential Deal Including Merger Of Its Consumer Healthcare Unit